If you have been watching Novo Nordisk lately, you are not alone. Anyone eyeing their portfolio these days has probably noticed the rollercoaster ride the stock has been on. After surging impressively over the past five years with a 74.0% return, Novo Nordisk shares have faced a sharp pullback, falling 10.3% over the past week and down 55.0% from last year’s level. Year to date, the price tells a similar story with a steep 45.4% decline.

Why the turbulence? Part of this comes down to shifting investor sentiment about big pharmaceutical companies and ongoing market developments that have influenced risk appetite recently. While less headline-grabbing than a breakthrough drug approval, changes in the way markets are pricing in growth expectations and future risks can have a real impact, both upward and downward. Interestingly, despite the volatility, Novo Nordisk’s track record shows its resilience over longer periods, which certainly catches the attention of value-oriented investors.

On that note, let’s talk numbers. The company currently boasts a valuation score of 5 out of 6, meaning Novo Nordisk is considered undervalued in five out of six major checks analysts look at. That high score puts it on the radar for anyone curious whether the market is being overly pessimistic.

So, how does Novo Nordisk stack up under the microscope of different valuation models, and is there an even better way to judge its true worth? Let’s dig into the approaches analysts use, and explore one method you might not expect, before you make your next move.

Why Novo Nordisk is lagging behind its peers

A Discounted Cash Flow (DCF) model forecasts a company’s future cash flows and then discounts those cash flows back to today’s value, giving investors a sense of what the business is intrinsically worth right now. For Novo Nordisk, analysts apply a 2 Stage Free Cash Flow to Equity approach, using their projections along with Simply Wall St’s longer-term extrapolations to look further into the future.

Currently, Novo Nordisk’s last twelve months’ Free Cash Flow stands at DKK 68.4 billion. Based on analyst consensus and extended forecasts, the company’s Free Cash Flow is expected to more than double over the next decade, potentially reaching DKK 215.1 billion by 2035. All estimates and projections are stated in Danish Krone (DKK).

The DCF calculation arrives at an intrinsic fair value of DKK 1,169 per share. With the stock currently trading at a price that represents a 70.2% discount to this estimated value, the model suggests that Novo Nordisk may be undervalued in the market at this time.

Result: UNDERVALUED

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Novo Nordisk.

Our Discounted Cash Flow (DCF) analysis suggests Novo Nordisk is undervalued by 70.2%. Track this in your watchlist or portfolio, or discover more undervalued stocks.

The Price-to-Earnings (PE) ratio is a popular metric for evaluating profitable companies like Novo Nordisk because it directly relates a company's share price to its per-share earnings, providing a snapshot of what investors are willing to pay for current profit levels. For companies with steady earnings, the PE ratio helps investors quickly gauge whether a stock is expensive or a potential bargain.

A "normal" or "fair" PE ratio is rarely set in stone. It changes according to expectations for growth and perceived risks. Higher anticipated earnings growth or lower risk often justify a higher PE, while slower growth or greater risk can drag the ratio down.

Currently, Novo Nordisk trades at a PE ratio of 13.94x. To put this in perspective, the average PE for its pharmaceutical industry peers is 24.28x, and the company’s peer group average stands even higher at 25.61x. At first glance, this means Novo Nordisk is trading at a significant discount compared to both benchmarks.

This is where Simply Wall St's “Fair Ratio” comes into play. Instead of just comparing Novo Nordisk to generalized peer or industry averages, the Fair Ratio incorporates vital factors like the company’s unique growth outlook, market cap, profit margins, and risk profile. This customized approach is more insightful because it recognizes that no two companies, even inside the same sector, deserve the exact same PE multiple.

For Novo Nordisk, the Fair Ratio is calculated at 29.41x. Comparing this to its actual PE of 13.94x suggests that the market is significantly undervaluing the stock based on its current and expected performance.

Result: UNDERVALUED

PE ratios tell one story, but what if the real opportunity lies elsewhere? Discover companies where insiders are betting big on explosive growth.

Earlier, we mentioned there is an even better way to understand valuation. Let’s introduce you to Narratives. A Narrative is more than just a set of numbers; it is your unique story about a company’s future, connecting what you believe about Novo Nordisk—its opportunities, risks, and competitive position—to specific forecasts and a customized fair value estimate.

On Simply Wall St’s Community page, Narratives make this process easy and accessible. They are used by millions of investors to link the company’s story, their assumptions for factors like future revenue growth, margins, and valuation multiples, and the resulting estimate of fair value all in one place. Narratives shine because they are dynamic. When news or earnings reports cause new information to emerge, these stories and their numbers update automatically, ensuring your view remains current.

This tool helps investors decide when to buy or sell. You set your Narrative’s fair value, then compare it to today’s price to see if Novo Nordisk looks appealing. For example, some market participants see Novo’s fair value as high as DKK 1,036 if growth outpaces expectations, while the most cautious view sets fair value closer to DKK 444, reflecting more modest assumptions and risks.

Do you think there's more to the story for Novo Nordisk? Create your own Narrative to let the Community know!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NOVO B.cpse.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com